The Bladder Carcinoma drugs in development market research report provides comprehensive information on the therapeutics under development for Bladder Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Bladder Carcinoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Bladder Carcinoma and features dormant and discontinued products.
GlobalData tracks 15 drugs in development for Bladder Carcinoma by 14 companies/universities/institutes. The top development phase for Bladder Carcinoma is phase ii with seven drugs in that stage. The Bladder Carcinoma pipeline has 15 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Bladder Carcinoma pipeline products market are: Immatics, Pan Cancer T and Sanofi.
The key targets in the Bladder Carcinoma pipeline products market include Cells Expressing Melanoma Antigen Preferentially Expressed In Tumors (Cancer/Testis Antigen 130 or Opa Interacting Protein 4 or OIP4 or Preferentially Expressed Antigen Of Melanoma or PRAME), Cells Expressing Nectin 4 (Ig Superfamily Receptor LNIR or Poliovirus Receptor Related Protein 4 or Nectin Cell Adhesion Molecule 4 or PVRL4 or NECTIN4), and Cells Expressing Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1).
The key mechanisms of action in the Bladder Carcinoma pipeline product include Cytotoxic To Cells Expressing Melanoma Antigen Preferentially Expressed In Tumors (Cancer/Testis Antigen 130 or Opa Interacting Protein 4 or OIP4 or Preferentially Expressed Antigen Of Melanoma or PRAME) with two drugs in Phase II. The Bladder Carcinoma pipeline products include six routes of administration with the top ROA being Intravenous and six key molecule types in the Bladder Carcinoma pipeline products market including Monoclonal Antibody Conjugated, and Gene-Modified Cell Therapy.
Bladder Carcinoma overview
Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. Symptoms include blood in the urine, pain with urination, and low back pain. It is caused when epithelial cells that line the bladder become malignant.Bladder cancer characteristically causes blood in the urine, which may be visible or detectable only by microscope. The best diagnosis of the state of the bladder is by way of cystoscopy.
For a complete picture of Bladder Carcinoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
